Dr. Pfeifer received his PhD in Applied Microbiology/Molecular Biology at the University of Saskatchewan. He went on to do a PDF in molecular genetics where he co-developed an insect-based protein expression system that was patented and licensed out of UBC. He was also directly involved in creating a small successful CRO that creates stable insect cell lines for the purpose of large scale expression of complex human therapeutic proteins. Further technology development led to the creation of functional cell-based assays for human GPCR’s, resulting in a second patent application that was spun out into NeuroTherapeutics Inc, which Dr Pfeifer joined as a senior scientist. After 18 months, NeuroTherapeutics closed its doors due to collapse of the biotech market and a lack of funding possibilities. Since the close of NeuroTherapeutics, Dr. Pfeifer has lead and managed several projects including: pharmacogenomics of aldoketoreductases and serotonin receptors in the Department of Pharmaceutical Sciences at UBC; and the genomics and proteomic analysis of spinal cord damage at iCORD. Dr Pfeifer has published over 30 papers, participated in two patent applications, completed a diploma in bioinformatics and recently participated in a training workshop on the use of mass spectroscopy for metabolomic analyses.